Project Grant R01CA309345
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $715K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) for the period of August 1, 2025, through July 31, 2030. The research focuses on developing antigen-specific radiosensitization through antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance the therapeutic index of radiotherapy. The project centers on two...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $418,176 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This award supports the continued advanced development and validation of programmable nucleic acid cytometry technology, specifically building upon the Institute's prior work with Programmable Enrichment via RNA Fluorescence In Situ Hybridization...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $1.056 million under the Cancer Treatment Research program (CFDA 93.395) effective August 20, 2025, with a completion date of July 31, 2032. This award supports research to elucidate mechanisms of therapy resistance in metastatic breast cancer, with particular focus on understanding breast cancer plasticity and acquired genetic alterations that drive...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This research initiative focuses on understanding and overcoming treatment resistance in locally advanced rectal cancer (LARC) patients undergoing total neoadjuvant therapy (TNT)—a combined treatment regimen consisting of radiation therapy,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute For Cancer Research a $452,540 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award supports research to develop and validate electronic nose (e-nose) technology utilizing volatile organic compounds (VOCs) in patient exhalates to predict and assess pathologic response to neoadjuvant therapy in patients with...
- Federal Project Grant Summary The National Cancer Institute awarded $1.504M to the Sloan-Kettering Institute for Cancer Research under the Cancer Cause and Prevention Research program (CFDA 93.393) on May 6, 2025, for a five-year project period concluding April 30, 2030. This Project Grant supports research to identify the genetic determinants of radiation-associated contralateral breast cancer (CBC) and develop comprehensive risk estimation models. The research leverages the WECARE Study, a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a Project Grant of $292,028 under the Cancer Research Manpower program (CFDA 93.398) beginning August 1, 2025, with a completion date of July 31, 2030. This grant supports a research project investigating genome instability associated with oncogene amplification (OA) and its therapeutic implications. The primary deliverable is advanced genomic research utilizing single-cell...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded Cold Spring Harbor Laboratory a $778,873 Project Grant on June 23, 2025, with a completion date of May 31, 2030. This award funds research to identify and validate SOAT1 (Sterol-O-Acyl Transferase 1) as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models and inducible degron systems...